William Blair Issues Negative Outlook for Exelixis Earnings

Key Points

• William Blair has lowered its Q3 2025 earnings estimate for Exelixis to $0.61 per share from $0.63, while maintaining an "Outperform" rating on the stock.
• The company's recent earnings report showed a net margin of 27.01% with a year-over-year revenue decline of 10.8%.
• Exelixis has a consensus rating of "Moderate Buy" with a target price of $44.53, and institutional investors own 85.27% of the company's stock.

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Analysts at William Blair decreased their Q3 2025 earnings estimates for shares of Exelixis in a report issued on Monday, October 20th. William Blair analyst A. Hsieh now expects that the biotechnology company will earn $0.61 per share for the quarter, down from their previous estimate of $0.63. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.12. The business had revenue of $568.26 million during the quarter, compared to analysts' expectations of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company's revenue for the quarter was down 10.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS.

A number of other analysts have also recently weighed in on EXEL. UBS Group set a $38.00 price target on shares of Exelixis and gave the stock a "neutral" rating in a research note on Wednesday, July 30th. Leerink Partners upgraded shares of Exelixis from a "market perform" rating to an "outperform" rating and set a $48.00 price target for the company in a research note on Tuesday. Stifel Nicolaus raised their target price on shares of Exelixis from $38.00 to $41.00 and gave the stock a "hold" rating in a research note on Tuesday, July 29th. Wall Street Zen upgraded shares of Exelixis from a "hold" rating to a "buy" rating in a research note on Friday, October 3rd. Finally, Jefferies Financial Group set a $50.00 price objective on shares of Exelixis and gave the company a "buy" rating in a research note on Tuesday, June 24th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $44.53.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $36.13 on Wednesday. The stock has a market cap of $9.73 billion, a P/E ratio of 17.37, a P/E/G ratio of 0.69 and a beta of 0.38. The firm has a fifty day moving average price of $38.73 and a 200 day moving average price of $40.02. Exelixis has a 1-year low of $27.86 and a 1-year high of $49.62.

Hedge Funds Weigh In On Exelixis

Institutional investors have recently modified their holdings of the company. Hemington Wealth Management grew its holdings in Exelixis by 211.3% in the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 522 shares during the period. Byrne Asset Management LLC grew its stake in Exelixis by 129.0% during the second quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company's stock worth $31,000 after buying an additional 400 shares during the period. Luminist Capital LLC lifted its position in shares of Exelixis by 2,740.0% during the second quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 685 shares in the last quarter. Family Legacy Financial Solutions LLC acquired a new position in shares of Exelixis during the second quarter worth $33,000. Finally, Bartlett & CO. Wealth Management LLC acquired a new position in shares of Exelixis during the first quarter worth $37,000. Institutional investors and hedge funds own 85.27% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.